Background Glioblastoma (GBM) is the deadliest and the most common primary brain tumor
in adults. The invasiveness and proliferation of GBM cells can be decreased through the …

Glioblastoma, the most common and aggressive primary brain tumors, carry a bleak
prognosis and often recur even after standard treatment modalities. Emerging evidence …

Dimethyl-celecoxib (DMC) is a close structural analog of the selective COX-2 inhibitor
celecoxib that lacks COX-2-inhibitory function. Thus, DMC is a promising drug for anti-tumor …

TMZ-resistance remains a main limitation in glioblastoma (GBM) treatment. TMZ is an
alkylating agent whose cytotoxicity is modulated by O6-methylguanine-DNA …

Temozolomide (TMZ) is used for the treatment of high-grade gliomas. Acquired
chemoresistance is a serious limitation to the therapy with more than 90% of recurrent …

Temozolomide (TMZ) resistance is frequent in patients with glioblastoma (GBM), a tumor
characterized by a marked inflammatory microenvironment. Recently, we reported that …

Gliomas are devastating primary tumors of the central nervous system and tend to recur
even after standard therapy. Celecoxib, the selective COX-2 nonsteroidal anti-inflammatory …

Abstract Background Selective cyclooxygenase (COX)-2 inhibitors elicit anti-proliferative
responses in various tumours, however the underlying anti-tumour mechanisms are unclear …

Cyclo-oxygenase (COX)-2 inhibitors may exert antitumour effects through COX-2-
independent mechanisms. This study investigated the effects of the COX-2 inhibitor …

The purpose of this study was to determine whether a combination treatment of
temozolomide with celecoxib is effective in the rat orthotopic glioma model. After stereotactic …